A novel naphthalimide derivative reduces platelet activation and thrombus formation via suppressing GPVI

Tzenge-Lien Shih1,2 | Kuan-Hung Lin2,3,4 | Ray-Jade Chen5,6 | Ting-Yu Chen3,6 | Wei-Ting Kao1 | Jen-Wei Liu1 | Hsueh-Hsiao Wang7 | Hsien-Yu Peng7 | Yu-Yo Sun8 | Wan-Jung Lu2,3,9,10

1Department of Chemistry, Tamkang University, New Taipei City, Taiwan
2Traditional Herbal Medicine Research Center, Taipei Medical University Hospital, Taipei, Taiwan
3Department of Pharmacology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
4Institute of Biomedical Sciences, MacKay Medical College, New Taipei City, Taiwan
5Division of General Surgery, Department of Surgery, Taipei Medical University Hospital, Taipei, Taiwan
6Department of Surgery, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
7Department of Medicine, Mackay Medical College, New Taipei City, Taiwan
8Department of Neurosciences, Center for Brain Immunology and Glia (BIG), University of Virginia School of Medicine, Charlottesville, VA, USA
9Department of Medical Research, Taipei Medical University Hospital, Taipei, Taiwan
10Graduate Institute of Metabolism and Obesity Sciences, College of Nutrition, Taipei Medical University, Taipei, Taiwan

Abstract

Naphthalimide derivatives have multiple biological activities, including antitumour and anti-inflammatory activities. We previously synthesized several naphthalimide derivatives; of them, compound 5 was found to exert the strongest inhibitory effect on human DNA topoisomerase II activity. However, the effects of naphthalimide derivatives on platelet activation have not yet been investigated. Therefore, the mechanism underlying the antiplatelet activity of compound 5 was determined in this study. The data revealed that compound 5 (5–10 μM) inhibited collagen- and convulxin- but not thrombin- or U46619-mediated platelet aggregation, suggesting that compound 5 is more sensitive to the inhibition of glycoprotein VI (GPVI) signalling. Indeed, compound 5 could inhibit the phosphorylation of signalling molecules downstream of GPVI, followed by the inhibition of calcium mobilization, granule release and GPIIb/IIIa activation. Moreover, compound 5 prevented pulmonary embolism and prolonged the occlusion time, but tended to prolong the bleeding time, indicating that it can prevent thrombus formation but may increase bleeding risk. This study is the first to demonstrate that the naphthalimide derivative compound 5 exerts antiplatelet and antithrombotic effects. Future studies should modify compound 5 to synthesize more
1 | INTRODUCTION

Normal haemostasis is a complicated process involving platelets and the coagulation cascade.1 When blood vessels are injured, circulating platelets adhere to exposed extracellular matrix proteins, such as von Willebrand factor and collagen. The exposed collagen can activate platelets through glycoprotein VI (GPVI). GPVI, a collagen receptor present on platelets, is associated with an immunoreceptor tyrosine-based activation motif (ITAM) containing the dimeric Fc receptor γ-chain. The binding of collagen to GPVI can activate Src family kinases (SFKs) Fyn and Lyn and subsequently induce ITAM tyrosine phosphorylation, thus resulting in the recruitment and activation of the tyrosine kinase Syk.2,3 A signalling complex in turn forms and conducts signalling cascade that activates phospholipase Cγ2 (PLCγ2), and its downstream effectors including protein kinase C (PKC) and mitogen-activated protein kinase (MAPKs), such as p38 MAPK, extracellular-signal-regulated kinase (ERK) and c-Jun amino-terminal kinase (JNK),2–4 promoting the release of ADP and thromboxane A2 that can further amplify platelet activation and recruit more platelets from the bloodstream to participate in haemostasis. Additionally, collagen activates protein kinase B (Akt) downstream of GPVI, which regulates platelet secretion and calcium mobilization.5,6 These activation cascades finally result in the formation of a firm platelet plug at the injury site to stop blood loss. Inappropriate regulation of the haemostatic process may lead to pathological consequences such as bleeding and thrombosis. Antiplatelet agents are used to prevent or treat secondary ischaemic stroke and myocardial infarction. However, the clinically significant bleeding has limited their use,7,8 necessitating the development of new antiplatelet agents with minimal bleeding risk.

Most compounds containing the naphthalimide moiety are fluorescent and have multiple biological activities including antitumour, anti-inflammatory and antiviral activities.7 Naphthalimide derivatives can easily intercalate into DNA and block cell division because of their flat structures.9,10 Moreover, these derivatives can intercalate into topoisomerase II (topo II), an enzyme with DNA breakage-reunion activity.10 Because of the aforementioned properties, naphthalimide derivatives can be potential antitumour agents. Moreover, many researchers have synthesized novel naphthalimide derivatives to develop more potent and efficient antitumour drugs with low toxicity.11–14 Previously, we synthesized several naphthalimide derivatives15,16 and evaluated their anticancer effect. Among these derivatives, compound 5 (Figure 1) exhibited the highest potency in inhibiting human DNA topo II activity (IC50 = 2.6 ± 0.1 μM) in murine B16F10 melanoma cells.16 In addition, 7b, a naphthalimide derivative, could inhibit lipopolysaccharide (LPS)-induced nuclear factor-kappa B (NF-κB) activation in RAW264.7 macrophages.17 Moreover, naphthalimides antagonize NS1 and influenza virus and thus inhibit viral replication; this process might be mediated by REDD1.18 Although these naphthalimide derivatives have been reported to be involved in several pathophysiological processes, their effects on platelet activation have not been investigated. Thus, in the present study, we examined the antiplatelet mechanism of compound 5. We expect that compound 5 be a lead compound for the development of novel antiplatelet agents for treating cardiovascular diseases.

2 | MATERIALS AND METHODS

2.1 | Materials

Thrombin, U46619, collagen and convulxin were purchased from Chrono-Log. Fluorescein sodium, phorbol 12,13-dibutyrate (PDBu), luciferase/luciferin and ADP were purchased from Sigma. Fura-2-AM; anti-phospho-Lyn (Tyr507), anti-phospho-Akt (Ser473), anti-phospho-Fyn (Tyr530) and anti-Lyn polyclonal antibodies (pAbs); and anti-Fyn monoclonal antibodies (mAbs) were purchased from Abcam. Anti-pleckstrin (p47) and anti-phospho-ERK1 (Thr202 /Tyr204)/ERK2 (Thr185/Tyr187) pAbs were purchased from GeneTex.

FIGURE 1 Structure of compound 5. Compound 5 consists of a naphthalimide framework (green box) in which the C4 position is linked with an ethylenediamine group (blue box) where the amino group couples with a 2-picolinic acid moiety (red box)
Anti-phospho-(Ser) PKC substrate, anti-phospho-JNK (Thr\(^{183}/\text{Tyr}^{185}\)), anti-phospho-p38 MAPK (Thr\(^{180}/\text{Tyr}^{182}\)) and anti-JNK pAbs; and anti-Akt, anti-p38 MAPK and anti-ERK mAbs were purchased from Cell Signaling. Horseradish peroxidase (HRP)-conjugated AffiniPure goat antirabbit, AffiniPure goat antimouse and AffiniPure donkey antigoat immunoglobulin G (IgG) were purchased from Jackson Immunoresearch. Allophycocyanin (APC)-conjugated PAC-1 antibodies and anti-P-selectin were purchased from Biolegend. Hybond-P polyvinylidene difluoride (PVDF) membrane was purchased from GE Healthcare Life Sciences. A SuperLight Chemiluminescent HRP kit was purchased from Bionovas.

### 2.2 Synthesis of compound 5

Compound 5 was synthesized as described previously.\(^{16}\) Compound 5 consists of a naphthalimide framework in which the C4 position is linked with an ethylenediamine group where the amino group couples with a 2-picolinic acid moiety (Figure 1). Compound 5 was dissolved in DMSO and stored at 4°C until use.

### 2.3 Preparation of platelet suspensions

This study was approved by the Taipei Medical University—Joint Institutional Review Board (TMU-JIRB-No. N202003148) and conformed to principles outlined in the Declaration of Helsinki. All volunteers provided informed consent prior to participation in this study. Washed human platelets were prepared as described previously.\(^{19}\) In brief, whole blood was obtained from healthy participants who had not received any medicines such as nonsteroidal anti-inflammatory drugs and aspirin during the preceding 2 weeks. Whole blood was drawn into polypropylene plastic tubes filled with an acid citrate/dextrose solution (A.C.D; 9:1, v/v). After mixing the whole blood was drawn into polypropylene plastic tubes filled with an acid citrate/dextrose solution (A.C.D; 9:1, v/v). After mixing the blood samples at 120 an acid citrate/dextrose solution (A.C.D; 9:1, v/v). After mixing the blood samples at 120

### 2.4 Platelet aggregation

Platelet aggregation was measured using a lumi-aggregometer (Payton) according to the turbidimetric method.\(^{19}\) In brief, platelet suspensions (3.6 x 10^8 cells/ml) were treated with compound 5 (1–100 μM) or an isovolumetric solvent control (0.1% DMSO) for 3 min. Subsequently, various agonists, namely collagen, thrombin and U46619, were added. Platelet aggregation was recorded for an additional 6 min.

### 2.5 Western blotting

Western blotting was performed as described previously.\(^{20}\) In brief, platelet suspensions (3.6 x 10^8 cells/ml) were pretreated with compound 5 (5 and 10 μM) or 0.1% DMSO for 3 min and then treated again with collagen for 6 min. After centrifugation, platelet pellets were immediately resuspended in lysis buffer (200 μl) for 1 h. The supernatants were collected after centrifugation at 5000 g for 5 min. The protein extracts (80 μg) were subjected to 8%-12% sodium dodecylsulfate-polyacrylamide gel electrophoresis. Separated proteins were then electrotransferred onto the polyvinylidene fluoride (PVDF) membrane through a semidry transfer (Thermo Fisher). The membrane was blocked with TBST (10 mM Tris-base, 100 mM NaCl and 0.01% Tween 20) containing 5% BSA for 1 h. After being washed three times, the membranes were incubated with various specific primary antibodies (1:1000). Subsequently, the membrane was incubated with HRP-conjugated antigoat, antimouse or anti-rabbit IgG (1:5000) for 1 h. Immunoreactive bands were developed using an electrochemiluminescence kit and analysed using Celvin S (Biostep).

### 2.6 ATP release and calcium mobilization

This method was performed as described previously.\(^{21}\) In brief, luciferase/luciferin and Fura 2-AM were used to detect ATP release and calcium mobilization respectively. The intensity of luminescence (ATP release) and the ratio (wavelength = 340/380 nm) of fluorescence (calcium mobilization) were measured using a Hitachi Spectrometer F-7000 in accordance with the manufacturer's instructions.

### 2.7 Flow cytometry

Flow cytometry was performed as described previously.\(^{20}\) In brief, 20 min after collagen stimulation, platelets were fixed and labelled with P-selectin or PAC-1 antibodies conjugated with APC for 30 min to detect the surface expression of P-selectin and the level of GPⅠb/Ⅲa activation respectively. After centrifugation and washing, platelets were suspended in 1 ml of phosphate-buffered saline and measured using a CytoFLEX flow cytometer (Beckman Coulter Life Sciences). In the flow cytometry setting, platelets were gated by a forward scatter and a side scatter, and the number of events at 10,000 counts was stopped. All experiments were performed at least three times to ensure reliability.

### 2.8 Animals

Male ICR mice (weighing 20–25 g and aged 5–6 weeks) were purchased from BioLasco. This project involving the use of animals was approved by the Affidavit of Approval of Animal Use Protocol—Taipei Medical University (LAC-2020-0074). All animal experiments...
were conducted in accordance with the Guide for the Care and Use of Laboratory Animals (Eighth Edition, 2011).

2.9 Washed mouse platelet preparation and aggregation study

Mouse blood was collected through cardiac puncture into a tube containing 100 μl of sodium citrate followed by gentle mixing. After centrifugation at 180 g for 5 min, PRP was obtained and mixed with A.C.D. (9:1, v:v). The platelet pellet was obtained after centrifugation at 1300 g for 15 min and then resuspended in Tyrode’s solution. A lumi-agregometer (Payton Associates) was used to measure platelet aggregation as described previously. Platelet suspensions (1.5 × 10⁹/ml) were stimulated using collagen (1 μg/ml) for 10 min; the extent of aggregation is expressed in light transmission units.

2.10 Pulmonary embolism in mice induced by collagen/epinephrine

Pulmonary thromboembolism was induced using collagen and epinephrine in male ICR mice according to the method described by DiMinno and Silver. In brief, mice were intravenously injected with a bolus dose of DMSO (solvent control), compound 5 (2.3 and 4.5 mg/kg) or aspirin (20 mg/kg, positive control). Mice received collagen (0.6 mg/kg) plus epinephrine (0.2 mg/kg) through tail vein injection. When the respiration is very weak and their heart was still beating, 0.5 ml of Evans blue solution (1% in saline) was injected into their heart. The lungs were excised and photographed. The mortality of mice was recorded over 24 h, and all surviving mice were sacrificed immediately after the experiment. Each group consisted of six animals. A formula for dose translation based on the body surface area was used to calculate the dose for use in the mice.

2.11 Thrombus formation in the mesenteric microvessels of mice irradiated by fluorescein sodium

Mice were anaesthetized using 3% isoflurane with oxygen-air mixture at a gas flow rate of 1.5–2 L/min. A bolus dose of compound 5 (1.2, 2.3 and 4.5 mg/kg), DMSO (solvent control) or aspirin (20 mg/kg, positive control) was intravenously administered for 30 min. Next, a 3-mm incision was made from the tail tip to induce tail bleeding. The bleeding tail stump was immediately immersed in saline, and the bleeding time, which was defined as the time until no sign of bleeding was observed for at least 10 s, was recorded. A formula for dose translation based on the body surface area was used to calculate the dose for use in the mice.

2.12 Tail-bleeding assay

Mice were anaesthetized using 3% isoflurane with oxygen-air mixture at a gas flow rate of 1.5–2 L/min. A bolus dose of compound 5 (1.2, 2.3 and 4.5 mg/kg), DMSO (solvent control) or aspirin (20 mg/kg, positive control) was intravenously administered for 30 min. Next, a 3-mm incision was made from the tail tip to induce tail bleeding. The bleeding tail stump was immediately immersed in saline, and the bleeding time, which was defined as the time until no sign of bleeding was observed for at least 10 s, was recorded. A formula for dose translation based on the body surface area was used to calculate the dose for use in the mice.

2.13 Statistical analysis

Data were analysed using analysis of variance with a post hoc analysis performed using the Newman-Keuls test. For survival analysis, survival curves were plotted using the Kaplan-Meier curves and analysed using the log-rank test, and all pair-wise multiple comparison procedures were performed by the Holm-Sidak method. Results are expressed as the mean ± standard error of the mean (SEM). p < 0.05 was considered statistically significant.

3 RESULTS

3.1 Compound 5 blocks collagen-induced platelet aggregation

Various platelet agonists were used to investigate the effect of compound 5 on platelet functions. As illustrated in Figure 2A, compound 5 (5–10 μM) significantly reduced collagen-induced platelet aggregation in washed platelets. The IC₅₀ was approximately 6.5 μM. Compound 5 could block thrombin- or U46619-stimulated platelet aggregation (Figure 2B,C, respectively) in washed platelets only at a relatively high concentration (25–100 μM). These findings suggest that compound 5 may be more sensitive to the inhibition of collagen-induced platelet activation. Moreover, compound 5 (5–10 μM) reduced platelet aggregation by the collagen receptor GPVI agonist convulxin (Figure 2D), (wavelength <520 nm) to induce endothelial damage-causing thrombus formation and subsequent vessel occlusion. The time required to occlude a microvessel was recorded. A formula for dose translation based on the body surface area was used to calculate the dose for use in the mice.
confirming that compound 5 may prevent platelet activation, at least in part, through GPVI signalling. In addition, ADP-induced platelet aggregation was conducted in PRP. As shown in Figure 2E,F, in PRP, compound 5 (10–100 μM) did not affect ADP-induced platelet aggregation; however, compound 5 affected collagen-induced platelet aggregation at a relatively high concentration (10–50 μM). This finding suggested that plasma protein binding may interfere with the efficacy of compound 5. The findings of these statistical analyses are illustrated in Figure 2G (washed platelets) and 2H (PRP). Compound 5 alone did not cause platelet activation as evidenced by observing shape change (Figure S1) and did not cause platelet cytotoxicity as detected by LDH cytotoxicity assay (Figure S2). On the basis of these results, we investigated the effect of compound 5 on collagen receptor downstream signalling in subsequent experiments.

3.2 | Compound 5 attenuates platelet activation by suppressing GPVI signalling

The binding of collagen to GPVI can activate SFKs Fyn and Lyn and subsequently activate PLC/2-PKC and MAPKs. Thus, we examined the effect of compound 5 on GPVI downstream signalling. As illustrated in Figure 3A and Figure S3, compound 5 (5–10 μM) inhibited the phosphorylation of Fyn, Lyn and p47 protein, a PKC substrate. Figure 3B–D showed the statistical analysis of Fyn, Lyn and p47 protein. Moreover, compound 5 did not affect the PKC activator PDBu-induced platelet aggregation, suggesting that compound 5 inhibits PKC activity by inhibiting the upstream pathway and not directly inhibiting PKC (Figure 3E). Collectively, these findings indicated that compound 5 can inhibit GPVI signalling.

Other signalling pathways responsible for collagen-induced platelet activation were examined. As shown in Figure 4, compound 5 did not affect collagen-induced Akt or p38 activation but significantly inhibited ERK and JNK activation, suggesting that compound 5 reduced collagen-induced platelet activation partly through inhibiting the activation of ERK and JNK.

3.3 | Compound 5 blocked granule release, calcium mobilization and GPIIb/IIIa activation

Platelet activation signalling can result in substance release from alpha and dense granules, such as ADP and fibrinogen that regulate...
platelet activation. Moreover, calcium release can promote granule release. Eventually, the inside-out signalling can activate GPIIb/IIIa. Thus, these activation events including granule release, calcium mobilization and GPIIb/IIIa are considered to be indicators of platelet activation. We investigated the effect of compound 5 on these activation events. Granule release was detected by measuring the release of ATP and the surface expression of P-selectin, which represent the release of dense and alpha granules respectively. As illustrated in Figure 5A, collagen markedly induced the release of P-selectin, which represent the release of dense and alpha granules respectively. The results revealed that compound 5 inhibited these two activation events (Figure 5C,D; Figure S4). These findings indicate that compound 5 inhibited ex vivo platelet aggregation and pulmonary embolism in mice.

3.4 Compound 5 inhibits ex vivo platelet aggregation and pulmonary embolism in mice

Platelets are involved in thrombosis, and antiplatelet agents are commonly used in clinical practice to prevent secondary thromboembolic events. The findings of this study demonstrated that compound 5 inhibited platelet activity in vitro. Thus, we investigated whether compound 5 exerts antithrombotic effects in vivo. To examine platelet aggregation ex vivo, whole blood was obtained from mice after they were injected with compound 5 or aspirin for 10 min. Subsequently, washed mouse platelets were prepared. Platelet aggregation was recorded for 10 min upon collagen treatment. As shown in Figure 6A, compound 5 significantly inhibited collagen-induced platelet aggregation. Moreover, aspirin (20 mg/kg; positive control) exhibited better inhibitory efficacy.

To examine pulmonary embolism in vivo, after mice were injected with compound 5 or aspirin for 10 min, collagen/epinephrine was injected to induce pulmonary embolism, which was observed through staining with Evans blue. The survival rate of mice was evaluated for 24 h. As shown in Figure 6B (left panel), compound 5 (2.3 and 4.5 mg/kg) and aspirin (20 mg/kg) effectively prevented pulmonary thrombosis. Moreover, compound 5 (4.5 mg/kg) and aspirin (20 mg/kg) significantly increased the survival rate by 50% and 67%, respectively, compared with DMSO (Figure 6B, right panel). These results revealed a similar inhibitory tendency of compound 5 and aspirin on ex vivo platelet aggregation and in vivo pulmonary embolism, suggesting that the antithrombotic effect of compound 5 is mediated, at least in part, through its antiplatelet activity.
3.5 Compound 5 delayed thrombus formation in mesenteric microvessels in mice

We employed another mouse thrombosis model to confirm the antithrombotic effect of compound 5. In this model, the endothelium was damaged through UV irradiation, resulting in vessel occlusion, which was observed and recorded using a real-time monitor. As illustrated in Figure 7A, vessel occlusion (arrows) after UV irradiation was observed at approximately 129.3 ± 10.8 s in the DMSO (solvent control)-treated group, and vessel occlusion was considerably delayed in the aspirin (positive control, 20 mg/kg)-treated group (approximately 436.4 ± 39.3 s, p < 0.001, n = 6, compared with the DMSO-treated group). Moreover, treatment with compound 5 (2.3 and 4.5 mg/kg) significantly prolonged the occlusion time by 117.0 ± 14.4 s and 167.2 ± 29.6 s (p < 0.01, n = 6; p < 0.001, n = 6, respectively). These findings suggest that compound 5 exerted an antithrombotic effect. However, new antiplatelet agents must exert strong antithrombotic effects with minimal bleeding risk. Thus, the mouse tail-bleeding assay was used to examine whether compound 5 affects haemostasis. As shown in Figure 7B, the aspirin-treated group exhibited a marked increase in bleeding time compared with the DMSO-treated group (aspirin, 561.2 ± 38.3 s vs. DMSO, 86.8 ± 26.6 s; p < 0.001). Treatment with only a high dose of compound 5 (4.5 mg/kg) significantly affected bleeding time.
(403.2 ± 87.7 s, p < 0.01, n = 6) compared with DMSO treatment. However, compound 5 at a low dose (1.2 and 2.3 mg/kg) nonsignificantly increased the risk of bleeding (163.5 ± 49.9 s, p = 0.34 and 196.7 ± 53.3 s, p = 0.35, respectively). These findings indicate that although compound 5 exerted antithrombotic effects, it tended to cause bleeding.

4 | DISCUSSION

This is the first study to demonstrate that compound 5 is more sensitive to the inhibition of collagen-mediated platelet activation, partly through suppressing GPVI signalling, followed by the inhibition of granule release, calcium mobilization and GPIIb/IIIa activation, eventually blocking platelet activation and thrombus formation (Figure 8). These findings indicate that naphthalimide-based compounds have antiplatelet and antithrombotic activities. Therefore, compound 5 may serve as a lead compound that can be further modified to synthesize more potent and efficient antiplatelet agents with minimal bleeding risk.

Naphthalimides have been used as a core scaffold for the development of antitumour and anti-inflammatory agents.9,10 They can intercalate with DNA and inhibit topo II due to their planar and heteroaromatic structure. Thus, many new naphthalimide derivatives have been developed as anticancer agents.9,10 We previously synthesized several naphthalimide derivatives and found them to exhibit cytotoxic effects on B16F10 melanoma cells and reduce lung metastasis at least partly through the inhibition of topo II activity.15,16 Among the naphthalimide derivatives we synthesized, compound 5 was found to exert the strongest inhibitory effect on topo II activity.16 At a concentration of 10 μM, compound 5 almost completely inhibited topo II activity. In the present study, we found that compound 5 (10 μM) blocked platelet aggregation and platelet activation events including granule release, calcium mobilization and GPIIb/IIIa activation. This finding implies that naphthalimides can serve as a core scaffold for antiplatelet agents. In addition, compound 5 was observed to be more sensitive to collagen-induced platelet activation compared with thrombin- and U46619-induced platelet activation, indicating its action on the collagen receptor downstream signalling pathway, such as Fyn, Lyn and PKC.

Platelets play a crucial role in arterial thrombosis that can cause heart attack and stroke. Atherosclerosis is the leading cause of heart attack and stroke. In addition to platelet activation, several risk factors such as lipid accumulation, endothelial cell activation, vascular smooth muscle cell proliferation and inflammation27 are involved in atherosclerosis. Previously, 7b, a naphthalimide derivative, was reported to inhibit inflammation through suppressing NF-κB activation in RAW264.7 macrophages.17 In addition, a novel naphthalimide (NAP-6) could selectively target breast cancer cells by activating the arylhydrocarbon receptor (AhR) pathway.28 Although the role of AhR remains controversial between pro- and anti-inflammatory responses in atherosclerosis,29,30 AhR was recently reported to play a
(A) Images showing the effect of different concentrations of compound 5 and aspirin on bleeding time.

- **DMSO**
  - 5 s
  - 130 s

- **1.2 mg/kg**
  - 5 s
  - 130 s

- **2.3 mg/kg**
  - 5 s
  - 130 s

- **4.5 mg/kg**
  - 5 s
  - 130 s

- **Aspirin 20 mg/kg**
  - 5 s
  - 130 s

(B) Graph showing the time in seconds for different treatments.

- **DMSO**
- **1.2**
- **2.3**
- **4.5**
- **Aspirin 20 mg/kg**

Significance levels: **p < 0.01**, ***p < 0.001***
protective role in promoting the maintenance of lesion cap integrity and reducing the transition of smooth muscle cells to chondromyocytes during atherosclerosis. Together, these observations suggest that naphthalimide derivatives exert anti-inflammatory effects to prevent cardiovascular diseases such as atherosclerosis and stroke. However, whether naphthalimide-based compound 5 exerts anti-inflammatory effect remains to be determined.

Akt is essential for collagen-induced platelet aggregation, and an SFK inhibitor was reported to completely inhibit GPVI-induced Akt phosphorylation. Fyn-deficient platelets exhibited decreased Akt phosphorylation induced by convulxin. Taken together, these findings suggest that SFK activates Akt in GPVI signalling. However, compound 5 inhibited the collagen-mediated phosphorylation of SFK (Lyn and Fyn) but did not affect the collagen-mediated phosphorylation of Akt. This discrepancy should be examined in future studies.

Platelets have MAPKs that mainly consist of three families: ERKs, JNKs and p38/SAPKs. MAPKs are activated by platelet agonists through the activation of their receptors and can regulate platelet activation and thrombus formation. ERK1/2 may regulate cPLA2 phosphorylation and AA metabolism into TxA2, subsequently causing dense granule release. JNK1 regulates dense granule release by affecting TxA2 generation. p38 regulates cPLA2 phosphorylation and activity as well as α-granule and dense granule secretion. MAPKs can support clot retraction and GPⅡb/Ⅲa activation. Moreover, pharmacological inhibition or gene deletion of MAPKs significantly prolonged thrombus formation. In the present study, compound 5 inhibited granule release, GPⅡb/Ⅲa activation and thrombus formation, in part through suppressing ERK and JNK phosphorylation.

Targeting the collagen receptor GPⅥ can be a favourable strategy for preventing thrombosis while preserving haemostasis. Patients with GPⅥ deficiency only exhibited mild bleeding. Moreover, GPⅥ-deficient mice exhibited protection against arterial thrombosis. In clinical trials, two classes of drugs, a humanized anti-GPⅥ Fab fragment (ACT01) and a dimeric GPⅥ-Fc fusion protein (Revacept), could inhibit the interaction between platelets and collagen but did not affect general haemostasis. In addition, studies have reported that fibrin and fibrinogen may activate GPⅥ and stabilize thrombi. These findings indicate that targeting...
GPVI may be a promising antithrombotic therapy. However, our in vivo study findings indicated that compound 5 could effectively prevent thrombus formation but showed a tendency to cause bleeding, especially at a high dose; this implies that compound 5 may affect other targets, such as the coagulation cascade, and the implication requires elucidation through further research. Therefore, although compound 5 may act as a lead compound for the design of new naphthalimide-based antiplatelet agents, the bleeding side effect must be eliminated or minimized during future drug development.

Glycoprotein VI was recently reported to promote metastasis by interacting with cancer cell-derived galectin-3. Platelet activation causing the formation of aggregates on the surface of circulating tumour cells may protect against immune cell attack. Previously, we demonstrated that naphthalimide derivatives could prevent lung metastasis of melanoma cells through the inhibition of topo II. Our present data revealed that a naphthalimide derivative (compound 5) could prevent platelet activation, likely through the inhibition of GPVI signalling. In addition to the inhibition of topo II activity, whether the antimitastatic effect of naphthalimide derivatives can be attributed to their ability to inhibit platelet activation should be examined in future studies.

In conclusion, our findings indicated that the naphthalimide derivative compound 5 could exert antiplatelet and antithrombotic effects, at least in part, through the suppression of GPVI signalling. This naphthalimide derivative can serve as a core scaffold for developing novel antiplatelet agents to treat patients with cardiovascular diseases if the potential adverse effect of bleeding is eliminated or minimized.

ACKNOWLEDGEMENTS
This work was supported by grants from the Ministry of Science and Technology of Taiwan (MOST 106-2320-B-715-006-MY3, MOST 109-2320-B-715-003-MY3, MOST 108-2320-B-038-063, MOST 109-2320-B-038-044-MY3, MOST 108-2320-B-038-029 and MOST 109-2320-B-038-054), Taipei Medical University Hospital (108TMU-TMUH-11 and 109TMUH-SP-01) and Mackay Medical College (MMC-RD-107-1B-13 and MMC-RD-108-1A-02). This manuscript was edited by Wallace Academic Editing.

CONFLICT OF INTEREST
The authors declare that there is no conflict of interest.

AUTHOR CONTRIBUTION
Tzenge-Lien Shih: Formal analysis (equal); Investigation (equal); Resources (lead); Writing-review & editing (equal). Kuan-Hung Lin: Conceptualization (lead); Funding acquisition (lead); Methodology (equal); Validation (equal); Writing-original draft (lead). Ray-Jade Chen: Funding acquisition (lead); Writing-review & editing (equal). Ting-Yu Chen: Data curation (equal); Formal analysis (equal); Investigation (equal). Wei-Ting Kao: Formal analysis (equal); Resources (equal). Jen-Wei Liu: Formal analysis (equal); Resources (equal). Hsueh-Hsiao Wang: Writing-review & editing (equal). Hsien-Yu Peng: Writing-review & editing (equal). Yu-Yo Sun: Writing-review & editing (equal). Wan-Jung Lu: Conceptualization (lead); Data curation (equal); Formal analysis (equal); Funding acquisition (lead); Validation (equal); Writing-original draft (lead); Writing-review & editing (lead).

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request. Some data may not be made available because of privacy or ethical restrictions.

ORCID
Wan-Jung Lu https://orcid.org/0000-0001-7664-4740

REFERENCES
1. Swieringa F, Spronk HMH, Heemskerk JWM, van der Meijden PEJ. Integrating platelet and coagulation activation in fibrin clot formation. Res Pract Thromb Haemost. 2018;2:450-460.
2. Borst O, Gawaz M. Glycoprotein VI - novel target in antiplatelet medication. Pharmacol Ther. 2021;217:107630.
3. Estevez B, Du X. New concepts and mechanisms of platelet activation signaling. Physiology (Bethesda). 2017;32:162-177.
4. Patel P, Naik UP. Platelet MAPKs a 20+year history: what do we really know? J Thromb Haemost. 2020;18:2087-2102.
5. Barry FA, Gibbins JM. Protein kinase B is regulated in platelet activation by the collagen receptor glycoprotein VI. J Biol Chem. 2002;277:12874-12878.
6. Kim S, Mangin P, Dangelmaier C, et al. Role of phosphoinositide 3-kinase beta in glycoprotein VI-mediated Akt activation in platelets. J Biol Chem. 2009;284:33763-33772.
7. Majithia A, Bhatt DL. Novel antiplatelet therapies for atherothrombotic diseases. Arterioscler Thromb Vasc Biol. 2019;39:546-557.
8. McFadyen JD, Schaff M, Peter K. Current and future antiplatelet therapies: emphasis on preserving haemostasis. Nat Rev Cardiol. 2018;15:181-191.
9. Kamal A, Bolla NR, Srikanth PS, Srivastava AK. Naphthalimide derivatives with therapeutic characteristics: a patent review. Expert Opin Ther Pat. 2013;23:299-317.
10. Tandon R, Luxami V, Kaur H, Tandon N, Paul K. 1,8-Naphthalimide: a potent DNA intercalator and target for cancer therapy. Chem Rec. 2017;17:956-993.
11. Ma J, Li Y, Li L, et al. A polyamine-based dinitro-naphthalimide conjugate as substrates for polyamine transporters preferentially accumulates in cancer cells and minimizes side effects in vitro and in vivo. Front Chem. 2020;8:166.
12. Singh I, Luxami V, Paul K. Synthesis and in vitro evaluation of naphthalimide-benzimidazole conjugates as potential antioxidant agents. Org Biomol Chem. 2019;17:5349-5366.
13. Van Quaquebeke E, Mahieu T, Dumont P, et al. 2,2,2-Trichloro-N-[2-[2-(dimethylamino)ethyl]-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin-5-yl]carbamoyl]acetamide (UNBS3157), a novel non-hematoxic naphthalimide derivative with potent antioxidant activity. J Med Chem. 2007;50:4122-4134.
14. Yildiz U, Kandemir I, Comert F, Akkok S, Coban B. Synthesis of naphthalimide derivatives with potential anticancer activity, their comparative ds- and G-quadruplex-DNA binding studies and related biological activities. Mol Biol Rep. 2020;47:1563-1572.
15. Lu YT, Chen TL, Chang KS, et al. Synthesis of novel C4-benzazole naphthalimide derivatives with potent anti-tumor properties against murine melanoma. Biol Med Chem. 2017;25:789-794.
16. Tung CH, Lu YT, Kao WT, et al. Discovery of a more potent anticancer agent than C4-benzazole 1,8-naphthalimide derivatives against murine melanoma. J Chin Chem Soc. 2020;67:1254-1262.
17. Shao J, Li Y, Wang Z, et al. 7b, a novel naphthalimide derivative, exhibited anti-inflammatory effects via targeted-inhibiting TAK1 following down-regulation of ERK1/2- and p38 MAPK-mediated activation of NF-kappaB in LPS-stimulated RAW264.7 macrophages. *Int Immunopharmacol*. 2013;17:216-228.

18. Mata MA, Satterly N, Versteeg GA, et al. Chemical inhibition of RNA viruses reveals REDD1 as a host defense factor. *Nat Chem Biol*. 2011;7:712-719.

19. Lu WJ, Li JY, Chen RJ, Huang LT, Lee TY, Lin KH. VAS2870 and VAS3947 attenuate platelet activation and thrombus formation via a NOX-independent pathway downstream of PKC. *Sci Rep*. 2019;9:18852.

20. Lien LM, Lin KH, Huang LT, et al. Licochalcone A prevents platelet activation and in vivo vascular thrombosis by cumbrianadina: regulation by integrin alphallibbeta3 inside-out but not outside-in signals. *J Biomed Sci*. 2020;27:60.

21. Hou SM, Hsia CW, Tsai CL, et al. Modulation of human platelet activation and thrombus formation through the inhibition of PLCgamma2-PKC, Akt, and MAPK pathways. *Int J Mol Sci*. 2017:18:1500.

22. DiMinno G, Silver MJ. Mouse antithrombotic assay: a simple method for the evaluation of antithrombotic agents in vivo. Potentiation of antithrombotic activity by ethyl alcohol. *J Pharmacol Exp Ther*. 1983;225:57-60.

23. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. *FASEB J*. 2008;22:659-661.

24. Lin KH, Kuo JR, Lu WJ, et al. Hinokitiol inhibits platelet activation and thrombus formation in vivo. *Biochem Pharmacol*. 2013;85:1478-1485.

25. Golebiewska EM, Poole AW. Platelet secretion: from haemostasis to wound healing and beyond. *Blood Rev*. 2015;29:153-162.

26. Shattil SJ, Hoxie JA, Cunningham M, Brass LF. Changes in the platelet membrane glycoprotein IIb.IIIa complex during platelet activation. *J Biol Chem*. 1985;260:11107-11114.

27. Basatemur GL, Jorgensen HF, Clarke MCH, Bennett MR, Mallat Z. Vascular smooth muscle cells in atherosclerosis. *Nat Rev Cardiol*. 2019;16:727-744.

28. Gilbert J, De Iuliiis GN, McCluskey A, Sakoff JA. A novel naphthalimide that selectively targets breast cancer via the arylhydrocarbon receptor pathway. *Sci Rep*. 2020;10:13978.

29. Bock KW. Human AHR functions in vascular tissue: Pro- and anti-inflammatory responses of AHR agonists in atherosclerosis. *Biochem Pharmacol*. 2019;159:116-120.

30. Wu D, Nishimura N, Kuo V, et al. Activation of aryl hydrocarbon receptor induces vascular inflammation and promotes atherosclerosis in apolipoprotein E-/- mice. *Arterioscler Thromb Vasc Biol*. 2011;31:1260-1267.

31. Kim JB, Zhao Q, Nguyen T, et al. Environment-sensing aryl hydrocarbon receptor inhibits the chondrogenic fate of modulated smooth muscle cells in atherosclerotic lesions. *Circulation*. 2020;142:575-590.

32. Chen J, De S, Damron DS, Chen WS, Hay N, Byzova TV. Impaired platelet responses to thrombin and collagen in AKT-1-deficient mice. *Blood*. 2004;104:1703-1710.

33. Adam F, Kauskot A, Nurdien P, et al. Platelet JNK1 is involved in secretion and thrombus formation. *Blood*. 2010;115:4083-4092.

34. Flevaris P, Li Z, Zhang G, Zheng Y, Liu J, Du X. Two distinct roles of mitogen-activated protein kinases in platelets and a novel Rac1-MAPK-dependent integrin outside-in retractile signaling pathway. *Blood*. 2009;113:893-901.

35. Leboeuf S, Kandrot-Perrus M, Avenard G, Favre-Bulle O, Billiard P. Design, development and characterization of ACT017, a humanized Fab that blocks platelet’s glycoprotein VI function without causing bleeding risks. *Mabs*. 2017;9:945-958.

36. Alshehri OM, Hughes CE, Montague S, et al. Fibrin activates GPVI in human and mouse platelets. *Blood*. 2015;126:1601-1608.

37. Basatemur GL, Jorgensen HF, Clarke MCH, Bennett MR, Mallat Z. Vascular smooth muscle cells in atherosclerosis. *Nat Rev Cardiol*. 2019;16:727-744.

38. Gilbert J, De Iuliiis GN, McCluskey A, Sakoff JA. A novel naphthalimide that selectively targets breast cancer via the arylhydrocarbon receptor pathway. *Sci Rep*. 2020;10:13978.